Abstract | Serious adverse drug reactions (SADRs) are a major cause of morbidity and mortality worldwide. Some SADRs may be predictable, based upon a drug's pharmacodynamic and pharmacokinetic properties. Many, however, appear to be idiosyncratic. Genetic factors may underlie susceptibility to SADRs and the identification of predisposing genotypes may improve patient management through the prospective selection of appropriate candidates. Here we discuss three specific SADRs with an emphasis on genetic risk factors. These SADRs, selected based on widesweeping clinical interest, are drug-induced liver injury, statin-induced myotoxicity and drug-induced long QT and torsades de pointes. Key challenges for the discovery of predictive risk alleles for these SADRs are also considered.
Adverse drug reactions (ADRs) are often classified as Type A and Type B. Type A reactions represent an extension of the drug's therapeutic effect; they occur relatively frequently, and they are typically dose-related. Examples include hypotension with anti-hypertensive therapy and bleeding episodes with warfarin. By contrast, Type B reactions are unpredictable, occurring only in susceptible individuals 1 ; they are often termed 'idiosyncratic' , reflecting our lack of understanding of their underlying mechanisms. ADRs are referred to as serious adverse drug reactions (SADRs) if they can be generally characterized as requiring hospitalization, prolonging hospitalization, being permanently disabling or fatal 2 . SADRs can arise through either Type A or B mechanisms.
The overall incidence of SADRs in hospitalized patients in the United States has been estimated at 6.2-6.7% and the incidence of fatal ADRs is estimated to be 0.15-0.3% (REF. 2 ). This results in over 2 million estimated SADRs among hospitalized patients annually, with more than 100,000 deaths, making these reactions a significant cause of death in the United States. Studies in Europe and Australia have yielded similar estimates 3 . The resulting cost burden is enormous, representing tens of billions of dollars, and has an impact on both the healthcare and the pharmaceutical industry internationally 4 .
Genomic approaches to SADRs
Identifying genetic risk factors for SADRs, particularly Type B reactions, could significantly decrease the healthcare costs and improve the process of drug development 5 . Characteristics of SADRs that increase the likelihood of informative genetic (or genomic) analysis include: evidence for a familial or genetic component; accepted criteria for unambiguous diagnosis; objective (for example, laboratory-based) diagnostic data; low background incidence; and availability of sufficient numbers of cases and appropriately matched controls 6 . Accrual of large numbers of cases will be necessary for the efficient study of genetic factors underlying SADRs. The world's growing biobanks represent a potential resource for studies identifying genetic and other determinants of both rare and common SADRs. Each of these data repositories contains variable amounts of clinical information and biological tissue, reflecting their unique design (for example, diseasebased, treatment-based and/or population-based). In particular, population-based biobanks may prove useful for testing the generalizability of findings in diverse population subgroups (in which background genetic variation and environmental factors, such as differences in concomitant drug use and diet, may affect the results).
Pharmacokinetics
The study of processes impacting absorption, distribution, metabolism and excretion of a drug and its metabolites in the body.
Pharmacodynamics
The study of the mechanism of action of a drug, including but not limited to processes such as receptor binding and signal transduction.
As discussed elsewhere 5 , for less common SADRs, such studies may require national or international consortia involving governmental agencies, healthcare systems, and pharmaceutical companies as well as academic medical centres. Control subjects for such studies should be matched for drug exposure, concomitant use of other agents that could affect the pharmacokinetics or pharmacodynamics of the drug in question, gender and ethnicity. It follows that large databases that contain accurate medication data are critical to this effort.
other desirable features for genetic analysis of SADRs include: information regarding the molecular mechanisms of drug action and pathways for metabolism and elimination that can inform selection of candidate genes for testing genetic polymorphisms; and appropriate cellular and animal models, or in-silico simulations, for testing the functional effects of candidate genotypes. BOX 1 highlights the key criteria needed for genetic analysis of SADRs.
one historical example of a gene-linked ADR is the association of glucose-6-phosphate dehydrogenase (G6PD) polymorphisms with haemolytic anaemia. Severe haemolytic anaemia can occur in G6PD-deficient patients after the ingestion of fava beans and after the use of certain anti-malarial drugs or sulphonamides 7 . Worldwide, more than 200 million people are affected by G6PD deficiency, making drug-induced haemolysis a significant concern, particularly in regions endemic for malaria 8 . other examples include severe prolonged muscle relaxation with suxamethonium in patients with cholinesterase deficiency 9 and haematologic toxicities in thiopurine-S-methyltransferase-deficient paediatric patients treated with the antineoplastic agent 6-mercaptopurine 10 . one common mechanism underlying SADRs is unusual drug accumulation due to polymorphisms in drug-metabolizing enzymes (or solute transporters); a second mechanism is variation in drug action due to changes in drug target genes 1 . Between 1976 and 2007, 28 drugs were withdrawn from the US market for safety reasons [11] [12] [13] (FIG. 1) , thus drug safety remains a top priority of regulatory agencies.
In response to growing concerns regarding SADRs, the US Food and Drug Administration (FDA), is developing a plan to modernize the drug-safety system and enhance post-approval safety activities 14 . SADRs that occur before marketing often result in the termination of drug development, whereas those that are identified only after FDA approval are in widespread clinical use. BOX 2 illustrates the drugs that have been found to be associated with genetic risk factors and have undergone FDA labelling changes. Thus, SADRs pose challenges both to patient care and to pharmaceutical development. The types of toxicities that have been associated with drugs withdrawn from the US market between 1976 and 2007 are summarized in FIG. 1 .
The cost of bringing a single new drug to market is now estimated to exceed $800 million 15 . most of this expense is incurred in the clinical trials that are required to demonstrate that the drug is safe and effective. Reducing the size and length of drug trials is therefore a high priority for the pharmaceutical industry. From the efficacy standpoint, there are several emerging strategies that should make it possible to reduce the size of many clinical trials, including the use of knowledge regarding the genetic heterogeneity of disease in order to target individuals that are most likely to benefit from new treatments. By contrast, there are currently no viable strategies to reduce the number of patients required in a clinical trial to demonstrate drug safety. Safety considerations can therefore dictate the high costs of drug development, at least until there is an improved understanding of the mechanisms underlying SADRs 5 . In principle, the identification of genetic risk factors for SADRs could lead to the safer use of drugs. Patient-related risk factors for a given SADR may include both genetic and non-genetic risk factors. Historically, it has been difficult to discern the genetic components underlying any particular SADR; however, new genetic and genomic approaches may facilitate the identification of biological risk markers and reveal novel underlying mechanisms.
At present, converging lines of evidence point to genetic factors in the pathogenesis of many predictable ADRs, and basing drug choice and/or dose on a patient's genetic make-up seems likely to result in improved drug efficacy and safety. of 27 drugs that are frequently cited in ADR studies, 59% are metabolized by at least one enzyme with a variant allele known to be associated with decreased drug metabolism 16 . Examples of other mechanisms predisposing patients to the development of a clinically relevant ADR include abacavir hypersensitivity 17 and carbamazepine-induced severe cutaneous ADRs 18 . Here, we review current knowledge of three major drug-induced toxicities: liver injury, myotoxicity and torsades de pointes, and focus on the identification of genetic risk factors that are associated with their occurrence.
Drug-induced liver injury
Description and significance. Drug-induced liver injury (DIlI) is a major reason for regulatory actions against marketing approval, removal from the market place and restriction of prescribing indications Hepatotoxicity (21%; 6) Nephrotoxicity (7%; 2) Cardiotoxicity (7%; 2) Torsades (21%; 6) Rhabdomyolysis (7%; 2) Other (37%; 10) Nature Reviews | Drug Discovery most drugs responsible for severe DIlI are not predictable hepatotoxins. Rather, they are completely safe over a wide range of doses for the vast majority of treated patients, but severely toxic to a small subset of patients 20 . The onset of liver injury is characteristically delayed weeks or months after starting therapy, and the liver injury is generally diffuse 19 . In most instances, it is unclear what makes some individuals susceptible to liver toxicity, but available data support a substantial genetic contribution. TABLE 1 summarizes some of the studies that have reported statistically significant associations between specific gene polymorphisms and susceptibility to DIlI. These risk factors involve polymorphisms in two major categories of genes: the highly polymorphic genes in the major histocompatibility locus on chromosome 6, which encode antigen-presenting proteins; and various polymorphic genes that encode drug metabolizing enzymes. Because the populations in these studies have generally been small, only common polymorphisms have been tested as susceptibility alleles for DIlI.
In a prospective study, idiosyncratic DIlI accounted for 11% of all patients with acute liver failure 21 . This would suggest that there are only about 200 cases of acute liver failure due to idiosyncratic DIlI per year in the US, assuming roughly 2,000 cases of acute liver failure occur annually 22 . on the other hand, asymptomatic elevations in liver chemistries, particularly of serum alanine aminotransferase (AlT), are commonly caused by drugs 23 . However, even large elevations in serum AlT do not necessarily indicate clinically important liver injury. This is because most patients with AlT elevations that are associated with DIlI appear to adapt to the event 19 .
Such patients have spontaneous resolutions of the AlT elevations despite continuing treatment. For example, 2 out of 100 patients treated with troglitazone -a peroxisome proliferator-activated receptor agonist for type II diabetes -developed AlT elevations that were three times over the upper limits of normal (Uln), but less than 1 in 1,000 patients developed symptomatic liver injury in an unmonitored situation 24 . Hence, patients with AlT elevations, even large ones, will not necessarily have the most clinically important determinants of severe idiosyncratic reactions (that is, the susceptibility factors for irreversible injury).
In contrast to serum AlT elevations, the presence of jaundice due to a drug generally indicates clinically important liver injury. It has been noted that there is approximately 10% mortality among patients who seek a physician after they become jaundiced due to hepatocellular injury (that is, hepatocellular jaundice) 25 . Based on the above observations, it seems likely that potentially life-threatening idiosyncratic DIlI will ultimately reflect the presence of at least two distinct sets of susceptibility factors in the host. The first set of factors involves a predisposition to low-level injury, typically reflected in AlT elevations. For drugs where toxicity is believed to result from a toxic metabolite produced in the liver, this first set of factors can include genetic variation in drug metabolizing and detoxifying enzymes or drug transporters, and may be relatively drug specific (see TABLE 1 for examples). The prevailing hypothesis is that this initial liver injury will be transient despite continued treatment with the drug, unless the patient has a second, probably unrelated, predisposition, which prevents adaptation and/or accelerates the initial injury. There are few clues as to the nature of these secondary factors, although some evidence suggests that the innate immune system and protective mechanisms present in the liver may be involved 26 . These secondary factors might be much less molecule specific, such as the association of G6PD deficiency with haemolytic anaemia, Box 1 | Criteria for informative pharmacogenetic SADR studies definition of serious adverse drug reaction (sAdr) phenotype Characteristics of SADRs that increase the likelihood of informative genetic/genomic analysis include:
• Evidence for a familial or genetic component.
• Accepted criteria for unambiguous diagnosis.
• Low background incidence.
• Availability of sufficient numbers of cases and appropriately matched controls.
Other desirable features include:
• Information regarding the molecular mechanisms of drug action that can inform selection of candidate genes and pathways for testing genetic polymorphisms.
• Appropriate cellular and animal models, or in-silico simulations, for testing functional effects of candidate genotypes.
Availability of adequate numbers of cases
Accrual of large numbers of cases is mandatory for understanding the genetic and other determinants in both rare and common adverse reactions to drugs. Percentage of total and number of cases shown in brackets. Cardiotoxicity refers to heart-related toxicities other than torsades de pointes. 'Other' refers to haemolytic anaemia (1), skin disease (1), immune toxicity (2), gastrointestinal toxicity (1), respiratory toxicity (1), fatal (1), neurotoxicity (1), blood-related toxicity (1) and birth defects (1).
which is induced by numerous drugs 7 . It has not been possible to test hypotheses about these secondary factors because there has never been a systematic collection of genomic DnA from patients with severe DIlI. The few genomic DnA collections to date have been from patients with generally mild DIlI, such as AlT elevations in clinical trials.
Prospective studies of DIlI, whether performed in an academic or industrial setting, are unlikely to be able to distinguish patients with this second set of predisposing factors from among those with the first set alone. This is because the implicated drug will usually be stopped when AlT elevations are detected and before jaundice would appear. These considerations led the national Institute of Diabetes and Digestive and Kidney Diseases of the national Institutes of Health to sponsor a cooperative agreement to create a Drug-Induced liver Injury network (DIlIn) 27 . The goal of DIlIn is to determine causation and enrol referred cases into ongoing clinical studies. one approach is summarized below.
Criteria for diagnosis of DILI. Among the SADRs, DIlI is one of the more difficult ones to confidently diagnose. There are no blood tests to confidently establish causality and liver biopsies are rarely conclusive. Several diagnostic instruments such as the Roussel Uclaf Causality Assessment method (RUCAm) and the maria & victorino (m&v) clinical scale have been proposed 28 , but clear diagnosis of DIlI includes multiple factors and should be made by a clinician with expertise in hepatology or gastroenterology. The key to making the correct diagnosis is exclusion of other potential causes of liver injury, which generally requires complete case data, including records of all clinical laboratory and radiologic results, and a full medical history to allow the evaluation of alternative causes. Hence, it becomes necessary to obtain the original source documentation for all patients. Interview with the patient and study-related physical examination, although desirable, is generally not necessary if the documentation is complete. Even with complete information, it is usually not possible to make a diagnosis of DIlI with 100% certainty because severe and even fatal liver injury occurs when no aetiology is evident; approximately 15% of patients with acute liver failure are in this 'idiopathic' category 21 . If such a patient recently started a new medication, the role of this medication needs to be evaluated, as the medication may have been causative or it might be erroneously implicated. It is therefore important that the number of prior reports of liver injury that are associated with the suspect medication are considered. In general, idiopathic liver failure occurs in approximately 1 in 1 million adults a year in the United States 26 . As a subset of these cases are likely to be attributable to a hepatotoxic process set in motion by a drug, the potential for genetic risk markers to reduce the overall frequency of unexplained liver failure is likely to be quite substantial.
Statin-induced muscle toxicity
Description and significance. multiple, large clinical trials have demonstrated that statins (3-hydroxy-3-methylglutaryl coenzyme A (HmG CoA) reductase inhibitors) reduce the incidence of both primary and secondary coronary artery disease in patients at risk [29] [30] [31] . Each of the six currently available statin drugs is regarded as both safe and efficacious. over the past several decades, experience with this class of drugs has expanded into millions of patients. As a result, statin-related muscle complications are becoming better characterized [32] [33] [34] . In general, the frequency of statin-related muscle complications depends on how the ADR is defined clinically. Statin-induced muscle complications appear to be dosedependent 34 , and they have been described diagnostically as myalgia (focal or diffuse muscle pain), myopathy (pain in the absence of inflammation), myositis (pain accompanied by a systemic inflammatory response) and rhabdomyolysis (severe muscle damage accompanied by damage in another organ, most notably the kidneys) 33, 34 .
Box 2 | FDA labelling changes in drugs associated with genetic risk factors 6-Mercaptopurine Gene TPMT. Individuals who are homozygous for an inherited defect in the TPMT (thiopurine S-methyltransferase) gene are unusually sensitive to the myelosuppressive effects of mercaptopurine and prone to developing rapid bone-marrow suppression following the initiation of treatment. Laboratory tests are available, both genotypic and phenotypic, to determine TPMT status. Substantial dose reductions are generally required for homozygous-TPMT deficiency patients (with two non-functional alleles) to avoid the development of life-threatening bone marrow suppression. Although heterozygous patients with intermediate TPMT activity may have increased mercaptopurine toxicity, this is variable, and most patients tolerate normal doses of drug. If a patient has clinical or laboratory evidence of severe toxicity, particularly myelosuppression, TPMT testing should be considered. In patients who exhibit excessive myelosuppression due to 6-mercaptopurine, it may be possible to adjust the mercaptopurine dose and administer the usual dosage of other myelosuppressive chemotherapy as required for treatment 130 .
Azathioprine
Gene TPMT. It is recommended that consideration is given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. The most common non-functional alleles that are associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal complete blood count (CBC) results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable 131 .
Warfarin
Gene CYP2C9; VKORC1. The recently revised warfarin product label adds CYP2C9 and VKORC1 genetic variations to the list of clinical considerations for warfarin use. The label's specific warfarin dose recommendations have not changed. The warfarin label provides information on how people with certain genetic differences in the two genes may need lower warfarin doses than people without these genetic variations. The CYP2C9 gene product is involved in the metabolism of warfarin and the VKORC1 gene product helps regulate the ability of warfarin to prevent blood from clotting. Patients with CYP2C9*2 and CYP2C9*3 genetic variations are at an increased risk of bleeding with warfarin therapy 132 . irinotecan Gene UGT1A1. Patients with reduced UGT1A1 activity, and those who are homozygous for the UGT1A1*28 allele, are at increased risk of neutropenia following initiation of irinotecan treatment. A reduced initial dose should be considered for patients who are homozygous for the UGT1A1*28 allele. Heterozygotes (carriers of one variant allele and one wild-type allele that results in intermediate UGT1A1 activity) may be at increased risk for neutropenia 133 
.
Gilbert's syndrome A common, mild liver disorder caused by reduced activity of glucuronyltransferase, an enzyme required for excreting bilirubin; typically it does not require treatment or pose serious complications.
Creatine kinase (CK). An enzyme often measured clinically as a severity marker of muscle damage.
The frequency of clinically significant muscle toxicity remains a matter of ongoing debate 33 Circulating levels of creatine kinase (CK) are often used clinically as a marker of severity for statin-induced muscle damage [33] [34] [35] . However, the presence of statin-induced muscle damage may or may not be accompanied by leakage of muscle enzymes into the blood [35] [36] [37] . For most statins, diffuse myalgias (or arthralgias) are reported in the absence of CK elevation in 1-5% of the subjects exposed 32 . myalgias with a mild to moderate elevation in circulating CK level (3-10-fold Uln) occur in less than 1% of cases 34, 38 . For lovastatin and simvastatin in particular, the prevalence of mild CK elevation appears to be approximately 6.4 cases per 1,000 patients 38 . This estimate decreases to 1.6 cases per 1,000 patients if the definition is restricted to only those subjects with a high degree of CK elevation 38 . In general, confirmed myopathy (defined clinically as CK levels that are greater than 10-fold Uln) occurs in less than 0.1% of patients on statin monotherapy 34, 35, 38 . In the absence of true myopathy, however, adverse muscle symptoms (or mild CK elevation) can still cause a patient (or their physician) to alter the course of their clinical care. For example, mild but diffuse myalgias will often cause a patient to consider switching to a different drug or discontinue statin therapy altogether. If the patient's laboratory data show a mild-to-moderate elevation in serum CK level, the physician may agree. In these situations, it is helpful if a baseline serum CK level, obtained before the initiation of therapy, is available.
A mild elevation in serum CK levels might represent an adequate phenotype for the resolution of genetic predictors. Recently, an association between a candidate drug metabolizing enzyme gene polymorphism (CYP3A5*3) and the degree of CK elevation in myotoxicity case subjects exposed to atorvastatin was reported 39 . In this retrospective study (n=68 cases and 69 controls), case status simply required an elevation in serum CK level greater than Uln (while the subject was on the drug); a compelling pain syndrome was not required for case assignment 39 .
There is precedent for a statin-induced myotoxicity phenotype represented by elevated circulating CK levels in the absence of pain. Draeger and colleagues have documented ultrastructural damage (for example, breakdown of T-tubules and sarcolemmal rupture) in skeletal muscle biopsies obtained from statin-exposed subjects with no myalgias 40 . Although the clinical significance of this latter phenotype (often termed 'asymptomatic myopathy') remains unclear, further studies are warranted to determine whether these subjects are at increased risk for progression to rhabdomyolysis.
As noted above, the frequency of rhabdomyolysis is extremely low. A review of the records of more than 250,000 patients treated with atorvastatin, pravastatin or simvastatin, revealed that rhabdomyolysis was reported at an incidence of 0.000044 events per person per year in subjects receiving monotherapy 41 . others have reported that rosuvastatin is associated with similarly low rates of This study examined the effect of tranilast on evoked Gilbert's syndrome, not hepatotoxicity. NSAID, non-steroidal anti-inflammatory drug; TGF-α, transforming growth factor α.
Phase I metabolism
Phase I reactions may occur by oxidation, reduction, hydrolysis, cyclization and decyclization reactions. The process of oxidation takes place in the presence of mixed function oxidases and mono-oxygenases in the liver.
Phase II metabolism
Phase II reactions (conjugation reactions) are usually detoxicating and involve the interactions of the polar functional groups of phase I metabolites.
rhabdomyolysis (at doses less than 40 mg) 42, 43 . Therefore, in the context of a severe statin-induced ADR (that is, rhabdomyolysis), which is known to occur at a very low frequency, it may be difficult to obtain sufficient cases to adequately assess genetic predictors. Case control studies designed to answer such a question will need to screen millions of patients exposed in order to identify and recruit an adequate number of study subjects.
Factors affecting risk.
Despite the dramatic clinical efficacy statins, prescribing them can be complicated due to the differential biochemical properties of each individual drug. Some statins are highly lipophilic whereas others are highly hydrophilic, so the overall kinetic profile for this therapeutic class differs on a drug-by-drug basis 44 . Statin kinetics are further modified by population-based differences in clinical factors, such as age, body size and body composition. The severity of atorvastatininduced muscle toxicity (defined by CK level only) has been reported to be associated with younger age 39 . It is conceivable that age-related differences in lean body mass (younger people have, proportionally, more lean body mass than older people) could be associated with higher serum CK levels as CK is derived through muscle turnover and muscle represents lean body mass. It has been reported that the severity of atorvastatin-induced muscle toxicity was associated with male gender 39 , but it is conceivable that this difference was attributable to participation bias. Conversely, it is also conceivable that this difference was due to gender differences in drug metabolism and elimination. The serum half-life for atorvastatin is known to be 20% shorter in women than in men 45 . Because the parent drug is metabolized more rapidly in women, it is plausible that men have a slightly greater exposure for any given dose. This hypothesis requires testing.
The degree to which genetic factors contribute to patient-to-patient variability in statin metabolism is an active area of investigation. Whereas some statins undergo a great deal of phase I metabolism 46 , others appear to undergo very little 47 . Even among the statins that undergo phase I oxidation, the primary enzyme may differ on a drug-by-drug basis. Atorvastatin is oxidized primarily by members of the cytochrome P450 (CYP) 3A family 48 . Although these enzymes are known to have a role in the metabolism of simvastatin as well, data have also suggested a role for CYP2D6 in the oxidation of simvastatin metabolites [49] [50] [51] [52] [53] . Fluvastatin, on the other hand, is metabolized to a great degree by CYP2C9 (REFS 54, 55) . Each of these enzymes -CYP2C9, CYP2D6 and CYP3A4/5 -is genetically polymorphic. Phase I drug metabolizing enzyme gene polymorphisms may therefore account for population differences in myotoxicity risk. Following oxidative phase I drug metabolism, many statins form hydroxyl intermediates (for example, atorvastatin is converted to 2-oH atorvastatin and 4-oH atorvastatin 48 , whereas simvastatin is converted to 3-oH simvastatin and 6-oH simvastatin 56 ). These hydroxy-statin derivatives are then subjected to additional modification, through phase II metabolism (conjugative enzymes) by UDP-glucuronosyltransferase-1 (UGT1) (REFS 53, 57) . This process may yield a variety of biologically active lactone derivatives (for example, 2-oH atorvastatin lactone 58 or simvastatin lactone 57 ).
Gemfibrozil is thought to alter the pharmacokinetics (and corresponding clinical outcomes) of various statin drugs through a UGT1-dependent interaction 57 . By inhibiting the glucuronidation of simvastatin hydroxy acid, gemfibrozil attenuates the biliary excretion of simvastatin and puts patients at increased risk of developing statin-related toxicity. Furthermore, polymorphism in UGT1 alters the risk of developing cerivastatin-related muscle complications in patients using other concomitant lipid-lowering agents 42, 57, 59, 60 . Whether similar interactions (at the level of UGT1) will alter other statin-related outcomes is undetermined, but recent data suggest that this is likely 39, 61 . membrane transporters are also thought to modulate a variety of statin-related clinical outcomes. Polymorphisms in candidate solute transporter genes (for example, organic anion transporters) have been associated with altered hepatic uptake of pravastatin 62, 63 , and studies have revealed that gemfibrozil attenuates the uptake of rosuvastatin 61 and cerivastatin 42, 60 through an interaction with these gene products. There is growing evidence that genetic variation in solute carrier organic anion transporter family, member 1B1 (SLCO1B1), in particular, might have an effect on subject variability in statin-related outcomes 4, 64 . As the respective gene products modulate the cellular transport of statins differentially 64 , it is tempting to speculate that SLCO1B1 gene polymorphisms might allow us to predict a subject's risk of developing statin-induced myotoxicity on a drug-by-drug basis 65 . This hypothesis is currently being tested.
TABLE 2 summarizes a number of polymorphisms already associated with statin-induced mytotoxicity. much of this work has been conducted within the framework of studying candidate genes. Genetic variability in phase I (oxidative) drug metabolizing enzymes may predispose subjects to a more severe form of myotoxicity in the context of statin therapy 39, 66 . However, not all statins 
Hypokalaemia
Hypokalaemia is a potentially fatal condition in which the body fails to retain sufficient potassium to maintain health. The condition is also known as potassium deficiency.
undergo phase I oxidation. Any model of genetic variability in statin disposition must therefore also include phase II metabolism and cellular processes known to affect drug transport 65 . To date, a subject's risk of developing statin-induced myotoxicity has been associated with genetic variability in at least three membrane transporters [66] [67] [68] . As gene expression studies provide additional molecular insight into the mechanisms underlying this SADR, interesting toxicodynamic candidate genes are also emerging 69, 70 .
Criteria for identifying statin-induced rhabdomyolysis.
Clinically, the most important SADR associated with statin therapy is rhabdomyolysis 41 . The clinical definition of rhabdomyolysis has recently been reviewed [33] [34] [35] . The Advisory Panel for the national Cholesterol Education Program (nCEP) defines rhabdomyolysis as a CK level greater than10-fold Uln with renal compromise, whereas the US FDA requires a CK level greater than 50-fold Uln with organ damage 30 . A 50-fold elevation in serum CK level typically equates to a circulating CK level of approximately 10,000 International Units (IU) per litre. Phenotyping strategies for research purposes may differ. one strategy that uses both outpatient and inpatient data for myotoxicity case finding is illustrated in FIG. 2 . In an alternative hospital-based strategy, Graham et al. have specifically identified cases of rhabdomylosis in statin-treated patients using the following three categories 41 : Hospital discharge diagnoses possibly indicative of severe muscle injury (combined with ancillary laboratory data such as urine myoglobin levels); evidence from medical records for severe muscle injury at the time of hospital admission with an admitting diagnosis of rhabdomyolysis; and CK levels above 10-fold Uln (severe rhabdomyolysis was defined as CK levels above 50-fold Uln -that is, CK greater than 10,000 IU per l).
Using the latter (most stringent) definition for the construction of genetic association studies, sufficient numbers of drug-induced rhabdomyolysis cases may be difficult to recruit. For research purposes, one alternative approach might be to identify genetic determinants of risk specifically associated with either mild to moderate CK elevation (3-10-fold Uln) or myopathy (greater than 10-fold Uln). At an estimated frequency of 0.1% (REFS 29, 30, 32) , investigators can expect to identify up to 10,000 potential myopathy case subjects for every 10 million patients exposed to statins. The implementation of such an effort will likely require the establishment of a coordinated multi-institutional study team, possibly at the global level
.
Drug-induced long QT syndrome Description and significance. The morphologically distinctive ventricular tachycardia termed 'torsades de pointes' occurs in 1-5% of patients treated with antiarrhythmic agents that are known to have QT prolonging properties [71] [72] [73] [74] [75] . When this occurs, there is also prolongation of the QT interval on the surface electrocardiogram (ECG), often most evident on the beat(s) just before the onset of the arrhythmia 71, 76, 77 ; and basic scientific studies have implicated abnormal cardiac repolarization -represented as the QT interval on the surface ECG -as an integral mechanistic feature of the syndrome [78] [79] [80] [81] [82] (FIG. 3) . Although a series of clinical factors have been identified 71, 76, 83, 84 , the reaction in an individual patient remains unpredictable. The basic electrophysiological mechanisms in this syndrome have been established and provide a series of candidate genes for initiating genomic analysis of risk, as discussed below.
This abnormal electrophysiological response to drug challenge can also occur, albeit much less commonly, with non-cardiovascular drugs 77, 85 . Despite its rarity, this SADR can be sufficiently alarming to upset the balance between risk and benefit that goes into approval or prescription of any drug. Indeed, the drug-induced long QT syndrome (lQTS) leading to fatal arrhythmias has been one of the most common causes for drug withdrawal from the marketplace in the last decade ( FIG. 1) , and preclinical and pre-marketing evaluation of QT prolonging potential of new drug candidates now represents a major effort in the pharmaceutical industry [85] [86] [87] .
Factors affecting risk. multiple clinical risk markers of torsades de pointes, notably hypokalaemia, hypomagnesaemia, underlying bradycardia, coexistent heart disease and female gender, have been identified and will need to be considered in the analysis of any comprehensive genotype-phenotype association study 71, 76, 84, [88] [89] [90] . Familial syndromes characterized by an association between Figure 2 | screening for patients with statin-induced mytotoxicity. In this example of automated case screening a search of an adverse drug reaction (ADR) database resulted in 5,000,000 patients with creatine kinase (CK) measurements and 200,000 of those patients were exposed to statins. These cases included 20,000 patients with elevated CK levels (over 500 units per L), which were linked to their patient charts and were subsequently screened for inclusion/exclusion criteria by trained research coordinators and lastly, by an expert physician. Age and gender matched controls are selected in a similar fashion. This figure was courtesy of R. K. Mareedu (Marshfield Clinic, Wisconsin, USA). 
Penetrance
The frequency, under given environmental conditions, with which a specific phenotype results from a predetermined genotype; it is usually given as a percentage.
Subclinical mutation carrier
A carrier of a mutation who does not manifest the pathological effects of the mutation.
abnormal cardiac repolarization, manifest as marked prolongation of the QT interval on the surface ECG, and a high risk for sudden cardiac death (SCD) were first described in the 1950s and 1960s , and ten disease genes for the congenital lQTS have been identified since 1995 (REFS 94-104). The two most commonly affected genes (KCNQ1, originally known as KvLQT1, and KCNH2 (HERG)) encode the voltage-gated potassium channels underlying the currents I Ks and I Kr , respectively. Six of these ten disease genes also encode ion channel proteins or ancillary (function-modifying) subunits, and the remaining two disease genes, ANK2 and CAV3, do not encode ion channels but are thought to modify channel function. The ankyrin-B protein encoded by ANK2 appears to target calcium-handling proteins to appropriate membrane subdomains within myocytes 97 , whereas the CAV3 gene encodes a caveolar protein that appears to modify sodium channel function 101 . Each disease-associated mutation above upsets the balance between inward depolarizing and outward repolarizing currents during cardiac repolarization in favour of increased net inward current, resulting in prolonged action potentials and hence, increased QT intervals on the surface ECG. virtually all drugs that cause torsades de pointes block I Kr /human ether-a-go-go-related (HERG) channels 85, [88] [89] [90] 105, 106 , supporting a link between the familial and drug-associated forms of the syndrome. This action potential prolongation is thought to be especially exaggerated in mid-myocardial (m cells) and Purkinje cells compared with those in epicardial and endocardial cells; the resulting increased heterogeneity in action-potential durations is then postulated to create the substrate for reentrant excitation that generates torsades de pointes 88, 107 . The role of m cells and of transmural heterogeneity has received considerable attention as a mediator of this (and other) arrhythmias, but this construct is not universally accepted 108, 109 . Early after-depolarizations in m or Purkinje cells, which are generated by inward currents, such as I na , I Ca-l or I ti , may serve as triggers to initiate this re-entry 107, 110 . Disease genes identified in congenital lQTS are high priority candidates for the drug-induced form of the syndrome. In addition, they implicate other genes that are directly or indirectly involved in the control of cardiac electrical signalling. one important finding that has emerged as families with the congenital lQTS are studied is variable penetrance of the clinical phenotype 111 . one way in which this feature of the disease may become manifest is the development of marked QT prolongation and arrhythmias following drug exposure of subclinical mutation carriers to QT-prolonging drugs [112] [113] [114] . TABLE 3 emphasizes that although HERG inhibition is the mechanism underlying QT prolongation by drugs, variants in other channels can exaggerate this effect, consistent with the concept of 'reduced repolarization reserve' discussed below. Furthermore, in a screen of the coding regions of 5 congenital lQTS disease genes (KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A) in ~90 patients with druginduced torsades de pointes, mutations compatible with the subclinical congenital syndrome were found in ~5% of them 114, 115 .An ANK2 screen in ethnic controls (165 patients with exaggerated drug-induced QT prolongation, most of whom also had torsades, and 280 patients with other congenital arrhythmia syndromes) identified 8 ANK2 non-synonymous cSnPs in 14 out of 635 (2.2%) subjects 116 . Three were found in more than one subject, and further in vitro studies demonstrated a range of functional defects that roughly correlated with the severity of the clinical presentations.
In addition, polymorphisms in the lQTS disease genes have also been implicated as increasing risk: D85n (KCNE1) 117 , S1103Y (SCN5A) 118, 119 , T8A (KCNE2) 115 and Q9E (KCNE2) 94 . Q9E was originally identified as a mutation based on its absence from over 1,000 normal individuals; however, this variant is now recognized as a relatively common polymorphism in AfricanAmericans. Two candidate gene analyses (148 and 174 SnPs) have suggested that variants in HERG and in KCNQ1 can modulate the normal QT interval and drug-induced lQTS 120 . most recently, a genome-wide analysis identified variants in NOS1AP (also known as CAPON), a putative subunit of neuronal nitric oxide synthase, as a modulator of the normal QT interval 121 , and thus by extension as a candidate for mediating drug-induced lQTS risk. b | Following a single dose of dofetilide, the rhythm reverted to sinus (the desired therapeutic effect), but the QT interval prolonged markedly, to 560 msec. c | Shortly after the patient developed an episode of typical torsades de pointes. The sinus beat just before the arrhythmia displayed a very long QT interval (greater than 640 msec) and the beat was preceded by a pause. These ECG features are typical of torsades de pointes due to anti-arrhythmic drugs as well as non-cardiovascular medications.
Pharmacogenetics
The study of how variations in a few genes affect the response to medications.
The vast majority of heartbeats in patients with congenital lQTS arise from normal sinus rhythm mechanisms and in many instances are even accompanied by normal QT intervals. Similarly, although I Kr block is now recognized as the major initiating mechanism in drug-induced torsades de pointes, not every patient receiving culprit drugs develops marked QT prolongation or arrhythmia. Indeed, the frequency of mutation carriers for the congenital syndrome is now estimated at 1 in 1,000 to 1 in 3,000, yet the frequency of torsades for many non-cardiovascular drugs (such as terfenadine or cisapride) is much lower, indicating that even exposure to a patient with the congenital syndrome may not elicit arrhythmia. This lack of a simple relationship between reduced I Kr and a manifest clinical phenotype indicates that risk can be modulated by a factor(s) beyond I Kr block alone. variable drug metabolism can be invoked in some cases of drug-associated torsades de pointes 122 but this is far from a universal explanation, and will not explain variability in the congenital syndrome. The concept of 'repolarization reserve' 123 has been developed to explain this variability in response to a reduction or block of I Kr ; the notion is that as multiple mechanisms contribute to normal repolarization, loss of function in one of these (for example, reduced I Kr ) might not lead to clinical consequences unless other lesions are present. Examples of such lesions are subclinical mutations in ion channel or other genes, or disordered electrogenesis, which is increasingly recognized in acquired diseases such as heart failure or left ventricular hypertrophy 123 . The physiological concept corresponds to thinking in contemporary genomics postulating gene-gene or gene-environment interactions as crucial modulators of clinical phenotypes, and may be equally applicable to other instances of rare genetically mediated drug-induced syndromes. Indeed, recent studies provide support for the idea that I Ks might be one important source of repolarization reserve that protects against torsades de points during I Kr block 124, 125 .
Criteria for identifying long QT and torsades de pointes. Diagnosis of lQTS and torsades de pointes is based exclusively on the interpretation of the surface ECG. Thus, it is critical in ascertaining cases that clear ECGs are documented in patients and control populations.
Corrected QT intervals of greater than 500-520 msec are generally considered indicative of lQTS. Torsades de pointes has a characteristic pattern on ECG, which is usually preceded by a stereotypical series of cycle length changes. Diagnosis of torsades is best made by clinicians with expertise in cardiology. Through well-designed pharmacogenetic association studies, the identification of genomic predictors of drug-induced QT prolongation has the potential to inform the safer use of existing medications and support the development of novel medications in the future. Such studies are also likely to lead to the identification of new genes that modulate cardiovascular disease in general.
Challenges in SADR pharmacogenetics
Population-based, post-approval monitoring for SADRs clearly represents a critical element of the overall risk management paradigm 126 . As evidenced from the above examples, pharmacogenetic evaluation of SADRs will require the interrogation of large patient databases containing well-characterized cases and carefully selected controls. A common feature among the three examples discussed above is the evidence that the extreme (versus intermediate) SADR phenotype may require the convergence of multiple risk factors, possibly involving distinct pathways; this might contribute to the rarity and the unpredictability of these reactions.
Partnerships or networks of scientists in healthcare systems, academia, regulatory agencies and industry are needed. non-uniform or non-standardized definitions of clinical phenotypes for SADRs are a major challenge in identifying genetic risk factors. Clearly phenotypes need standardization so that partnerships can be formed to ascertain cases and controls, and to facilitate replication studies. Such standardization will require leadership and groups of scientists, clinicians and regulators must participate in such a process. Improved recording of medication data, including drug dose and use of other medications, in large epidemiologic studies and in records linked to biobanks is also critical. A related issue, given that phamacokinetic mechanisms are of crucial importance for many SADRs, is to consider the extent to which results from different drugs in the same class can be pooled. Effective procedures for enlisting the participation of physicians and patients in research protocols, including the collection and transfer of clinical information, DnA, plasma and/or other tissue specimens must be developed. Confidentiality and ethical issues must be considered in the design and implementation of clinical studies aiming to archive DnA and tissue.
Project-specific logistics regarding the approval to conduct research is a pivotal consideration. Careful attention to institutional review board approval for individual projects is essential, with the appropriate stipulations regarding protection of human subjects and privacy. Although we have partly addressed these issues, it is likely that the complexity of implementing such projects will increase with the growing number of study sites and questions.
Although beyond the scope of this Review, statistical and methodological issues regarding genetic association studies must also be explicitly and continually addressed, allowing flexibility and revised approaches during the process of data gathering and analyses 127, 128 . Recent studies have suggested that new candidate mechanisms for various common diseases may be discovered with genome-wide association studies 129 . However, such studies require a large number of samples, especially if the effect sizes of individual SnPs are small. Sample size remains a key challenge in studying the genetics of SADRs. Furthermore, current genome-wide association studies assume that common variants will associate with common diseases. Because of rarity, some SADRs do not conform to this assumption. Thus, using genome-wide association analysis to identify less common risk alleles for SADRs will require even larger sample sizes. new technologies for rapid sequencing will help in the identification of less common variants. Candidate gene studies can be performed with fewer samples; however, candidate gene studies require some knowledge of mechanism, which is not available for many cases of SADRs. Investigators must be versed in issues regarding genetic test performance characteristics, epistasis and sources of confounding (for example, population stratification and potential effects of environmental factors, such as diet), and should be able to minimize threats to both internal and external validity as appropriate.
Several regional networks to study SADRs have been established, including a network in Canada, focused on SADRs in children and one in Europe (EUDRAGEnE) that is focused on six SADRs in multiple European populations. BOX 3 lists networks that are focused on SADRs with efforts in genetics. These networks together with new networks from other communities could form a global consortium with the goal of standardizing phenotypes and more effectively conducting studies to identify genetic risk factors for SADRs 5 .
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